CYTOMX THERAPEUTICS, INC.
Last · —$2.23-0.095 (-4.09%)live · yahoo · 0s ago
Market cap$485.92M—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
| Revenue | $18.3M |
|---|---|
| Operating income | $-43.5M |
| Net income | $-38.9M |
| Free cash flow | $-43.6M |
| Operating margin | -237.4% |
| Net margin | -212.6% |
| Return on equity | -12.9% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-16
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -26.7%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -99.2%
- Cash Runway Low — Cash runway ~0.2 years
- Accumulated Deficit High — Accumulated deficit / equity 719%
- Rd Intensity High — R&D/Revenue 90.2%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.07
Est. revenue
10.5M
Press & signals
- GlobeNewswire
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
- GlobeNewswire
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
- GlobeNewswire
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
Documents
FormReporting forFiledFlags